…
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 7593.00M | 5269.00M | 5513.00M | 8353.00M | 6782.00M |
| Minority interest | -331.00M | -344.00M | -159.00M | 78.00M | 50.00M |
| Net income | 5957.00M | 3434.00M | 5164.00M | 6668.00M | 5365.00M |
| Selling general administrative | 14617.00M | 14844.00M | 14822.00M | 12738.00M | 12242.00M |
| Gross profit | 25986.00M | 25964.00M | 25177.00M | 148436.00M | 140710.00M |
| Reconciled depreciation | 2775.00M | 2775.00M | 3005.00M | 2937.00M | 2923.00M |
| Ebit | 8974.00M | 9692.00M | 9034.00M | 9503.00M | 8352.00M |
| Ebitda | 11607.00M | 11446.00M | 10846.00M | 12440.00M | 11275.00M |
| Depreciation and amortization | 2633.00M | 1754.00M | 1812.00M | 2937.00M | 2923.00M |
| Non operating income net other | - | - | - | 434.00M | -1349.00M |
| Operating income | 9129.00M | 9417.00M | 8536.00M | 9503.00M | 8352.00M |
| Other operating expenses | 265823.00M | 237704.00M | 186729.00M | 171668.00M | 167490.00M |
| Interest expense | 1381.00M | 1435.00M | 1446.00M | 1228.00M | 1208.00M |
| Tax provision | 1493.00M | 1491.00M | 141.00M | 1607.00M | 1367.00M |
| Interest income | 1432.00M | 3990.00M | 1524.00M | 1228.00M | 1208.00M |
| Net interest income | -1408.00M | -1435.00M | -1410.00M | -1228.00M | -1208.00M |
| Income tax expense | 1345.00M | 1491.00M | 141.00M | 1607.00M | 1367.00M |
| Total revenue | 274952.00M | 247121.00M | 195265.00M | 180642.00M | 174272.00M |
| Total operating expenses | 16857.00M | 16547.00M | 16641.00M | 13186.00M | -288953.00M |
| Cost of revenue | 248966.00M | 221157.00M | 170088.00M | 32206.00M | 33562.00M |
| Total other income expense net | -1536.00M | -4148.00M | -3023.00M | -1150.00M | 121463.00M |
| Net income from continuing ops | 6288.00M | 3778.00M | 5451.00M | 6668.00M | 5415.00M |
| Net income applicable to common shares | 5957.00M | 3434.00M | 5164.00M | 6668.00M | 5365.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 157919.00M | 155881.00M | 152761.00M | 143932.00M | 154889.00M |
| Intangible assets | 28560.00M | 32243.00M | 30863.00M | 32492.00M | 34102.00M |
| Other current assets | 4032.00M | 9898.00M | 6162.00M | 2201.00M | 12260.00M |
| Total liab | 116045.00M | 114638.00M | 106410.00M | 98981.00M | 107705.00M |
| Total stockholder equity | 41713.00M | 41033.00M | 46223.00M | 44872.00M | 47112.00M |
| Deferred long term liab | - | - | - | 7751.00M | 8346.00M |
| Other current liab | 45091.00M | 17185.00M | 37388.00M | -10768.00M | -9200.00M |
| Common stock | 4.00M | 4.00M | 4.00M | 4.00M | 4.00M |
| Capital stock | 4.00M | 4.00M | 4.00M | 4.00M | 4.00M |
| Retained earnings | 47865.00M | 43519.00M | 41652.00M | 37874.00M | 32593.00M |
| Other liab | - | - | - | 29306.00M | 33008.00M |
| Good will | 44924.00M | 44370.00M | 44259.00M | 45811.00M | 45811.00M |
| Other assets | 14499.00M | 14442.00M | - | 32160.00M | 43965.00M |
| Cash | 7676.00M | 7550.00M | 7822.00M | 5924.00M | 5081.00M |
| Cash and equivalents | 7676.00M | 7550.00M | - | 5924.00M | 5081.00M |
| Total current liabilities | 56342.00M | 57979.00M | 48716.00M | 10768.00M | 9200.00M |
| Net debt | 23787.00M | 24422.00M | 23108.00M | 25169.00M | 28589.00M |
| Short term debt | 592.00M | 3035.00M | 2775.00M | 2993.00M | 2545.00M |
| Short long term debt | 592.00M | 3035.00M | 2775.00M | 2993.00M | 2545.00M |
| Short long term debt total | 31463.00M | 31972.00M | 30930.00M | 31093.00M | 33670.00M |
| Other stockholder equity | -3350.00M | -149.00M | 6431.00M | 8389.00M | 15399.00M |
| Property plant equipment | 3651.00M | 3654.00M | - | 4149.00M | 3692.00M |
| Total current assets | 47814.00M | 48870.00M | 37351.00M | 28790.00M | 26096.00M |
| Long term investments | 12175.00M | 665.00M | 925.00M | 16288.00M | 18438.00M |
| Net tangible assets | - | - | - | -33365.00M | -32801.00M |
| Short term investments | 970.00M | 665.00M | 925.00M | 905.00M | 920.00M |
| Net receivables | 28768.00M | 24065.00M | 17722.00M | 21961.00M | 20095.00M |
| Long term debt | 30871.00M | 28937.00M | 28155.00M | 28034.00M | 31097.00M |
| Inventory | 7338.00M | 6692.00M | 5645.00M | 4777.00M | 3722.00M |
| Accounts payable | 10659.00M | 37759.00M | 8553.00M | 7775.00M | 6655.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 13.00M | 18.00M |
| Accumulated other comprehensive income | -2806.00M | -2341.00M | -1864.00M | -1395.00M | -884.00M |
| Common stock total equity | - | - | - | 4.00M | 4.00M |
| Retained earnings total equity | - | - | - | 37874.00M | 32593.00M |
| Treasury stock | - | - | - | -21844.00M | -14175.00M |
| Non currrent assets other | 14499.00M | 14442.00M | 18238.00M | -82982.00M | -84828.00M |
| Non current assets total | 110105.00M | 107011.00M | 115410.00M | 82982.00M | 84828.00M |
| Long term debt total | 30871.00M | 28937.00M | - | 28100.00M | 31125.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -4552.00M | -2102.00M | -5174.00M | -587.00M | -765.00M |
| Change to liabilities | - | - | - | 1865.00M | -77.00M |
| Total cashflows from investing activities | -4407.00M | -2102.00M | - | 3098.00M | -3611.00M |
| Net borrowings | -667.00M | 1060.00M | - | -500.00M | 800.00M |
| Total cash from financing activities | -6421.00M | -7647.00M | -4294.00M | -11240.00M | -8212.00M |
| Change to operating activities | - | - | - | 2338.00M | 2605.00M |
| Net income | 6288.00M | 3778.00M | 5164.00M | 6746.00M | 5415.00M |
| Change in cash | 126.00M | 594.00M | 2361.00M | 428.00M | -4697.00M |
| Begin period cash flow | 7550.00M | 8337.00M | 5976.00M | 5548.00M | 10245.00M |
| End period cash flow | 7676.00M | 8931.00M | 8337.00M | 5976.00M | 5548.00M |
| Total cash from operating activities | 9601.00M | 10363.00M | 11813.00M | 8656.00M | 7191.00M |
| Issuance of capital stock | 203.00M | 305.00M | 185.00M | 389.00M | 326.00M |
| Depreciation | 2775.00M | 2775.00M | 3035.00M | 2937.00M | 2923.00M |
| Other cashflows from investing activities | -3482.00M | -838.00M | - | 4393.00M | -3611.00M |
| Dividends paid | 1611.00M | 1567.00M | 1450.00M | 1384.00M | 1341.00M |
| Change to inventory | -646.00M | -1032.00M | -868.00M | -1055.00M | 143.00M |
| Change to account receivables | -4630.00M | -7854.00M | -2202.00M | -2275.00M | -3232.00M |
| Sale purchase of stock | -3621.00M | -7034.00M | -2284.00M | -7607.00M | -7742.00M |
| Other cashflows from financing activities | -726.00M | -411.00M | -469.00M | -2138.00M | 999.00M |
| Change to netincome | - | - | - | -1647.00M | -225.00M |
| Capital expenditures | 1212.00M | 1406.00M | 1573.00M | 1295.00M | 1154.00M |
| Change receivables | - | - | - | -2275.00M | -3232.00M |
| Cash flows other operating | - | - | - | 2085.00M | 2027.00M |
| Cash and cash equivalents changes | - | - | - | 514.00M | -4632.00M |
| Change in working capital | 201.00M | 1192.00M | 3488.00M | 620.00M | -872.00M |
| Stock based compensation | - | 308.00M | 286.00M | 264.00M | 268.00M |
| Other non cash items | 11.00M | 2713.00M | 1499.00M | -1431.00M | 141.00M |
| Free cash flow | 8389.00M | 8957.00M | 10240.00M | 7361.00M | 6037.00M |
Sector: Healthcare Industry: Healthcare Plans
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CI Cigna Corp |
9.97 3.37% |
305.41 | 11.94 | 8.68 | 0.27 | 1.80 | 0.36 | 7.93 |
| UNH UnitedHealth Group Incorporated |
4.94 1.22% |
409.38 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| CVS CVS Health Corp |
-11.14 12.19% |
80.27 | 55.65 | 10.80 | 0.25 | 1.32 | 0.42 | 17.09 |
| ELV Elevance Health Inc |
- -% |
434.18 | 18.47 | 14.58 | 0.45 | 2.05 | 0.56 | - |
| HUM Humana Inc |
-0.45 0.11% |
417.42 | 38.47 | 26.45 | 0.33 | 2.54 | 0.39 | - |
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
900 Cottage Grove Road, Bloomfield, CT, United States, 06002
860 226 6000
65669
| Name | Title | Year Born |
|---|---|---|
| Mr. David Michael Cordani | Pres, CEO & Chair of the Board | 1965 |
| Mr. Brian C. Evanko | Exec. VP & CFO | 1977 |
| Ms. Nicole Susan Jones | Exec. VP & Gen. Counsel | 1970 |
| Mr. Eric Paul Palmer | Pres & CEO of Evernorth | 1976 |
| Mr. Paul Sanford | Exec. VP of Operations | 1968 |
| Ms. Mary Terese Agoglia Hoeltzel CPA | Sr. VP of Tax & Chief Accounting Officer | NA |
| Ms. Noelle K. Eder | Exec. VP & Global Chief Information Officer | 1970 |
| Mr. Ralph Giacobbe | Sr. VP & Head of Investor Relations | NA |
| Mr. Everett Neville | Exec. VP of Strategy, Corp. Devel. & Solutions | 1965 |
| Ms. Cynthia Ryan | Exec. VP & Chief HR Officer | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.